



Dr. G. N. Singh  
DRUGS CONTROLLER GENERAL (INDIA)

**Central Drugs Standard Control Organization**

Directorate General of Health Services

Tele – 011-23236965

Fax - 011 -23236973

Email :- [dci@nic.in](mailto:dci@nic.in)

Web : [WWW.cdsc.nic.in](http://WWW.cdsc.nic.in)

FDA Bhawan, Kotla Road, New Delhi –110002.

F.No. DCG(I)/Misc./2016/(05)

Dated the 07<sup>th</sup> January, 2016

To,

All State Drug Controllers

**Subject: Use of Albendazole 400 mg tablets as co-administration for Lymphatic Filariasis elimination programme under National Health Programme of the Government of India in collaboration with WHO – regarding.**

Sir,

Lymphatic Filariasis has been targeted for elimination by the year 2020 as per the resolution of World Health Assembly in 1997. The global programme for elimination of Lymphatic Filariasis (ELF) was launched in the year 2000 covering almost all the 83 endemic countries. WHO recommended strategy for ELF is yearly single dose of DEC + Albendazole in all endemic areas except those areas where onchocerciasis is present where the combination is ivermectin with Albendazole.

The Government of India vide their letter No. T.14020/99/2006-Mal. Dated 11<sup>th</sup> September, 2006 conveyed approval for use of single annual dose of co-administration of DEC + Albendazole for elimination of Lymphatic Filariasis in the country (**Annexure – I**).

Albendazole is being supplied free of cost as global commitment of LF Elimination through M/s. GSK.

As the drug is supplied by M/s. GSK as donation through WHO for the programme for free distribution under the National Health Programme for elimination of Lymphatic Filariasis and is not marketed for sale in the country. In the circumstances, the compliance to the labeling requirements which are related to the sale of drugs through chemist shop is not considered necessary.

In view of this it is requested that the Drug Inspectors or other such field staff should be advised accordingly for smooth implementation of the programme which was initiated in 2004 and is targeted to be completed by 2020.

**Yours faithfully,**



**(Dr. G. N. Singh)  
Drugs Controller General (India)**

Copy forwarded to:

Zonal / Sub-zonal offices of CDSCO

Copy forwarded for information to

1. PPS to Secretary, H&FW, MoHFW, Nirman Bhawan, New Delhi
2. PPS to DGHS, Nirman Bhawan, New Delhi
3. PPS to AS & MD, MoHFW, Nirman Bhawan, New Delhi
4. WHO Country office, New Delhi
5. Director, NVBDCP, Delhi

